XML 55 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
EPS Calculation (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Reconciliation of the Earnings and Shares Used in Calculating Basic and Diluted EPS
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the years ended December 31, 2023, 2022 and 2021:
 
 For the Year Ended December 31,
(In Thousands, Except Per Share Amounts)202320222021
Basic Earnings/(Loss) per Share:
   
Net income/(loss) to common stockholders
$80,164 $(231,581)$328,870 
Dividends declared on preferred stock(32,875)(32,875)(32,875)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— (627)(1,044)
Net income/(loss) to common stockholders - basic
$47,289 $(265,083)$294,951 
Basic weighted average common shares outstanding102,215 103,153 110,704 
Basic Earnings/(Loss) per Share
$0.46 $(2.57)$2.66 
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic
$47,289 $(265,083)$294,951 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— — 1,044 
Interest expense on Convertible Senior Notes— — 15,668 
Net income/(loss) to common stockholders - diluted
$47,289 $(265,083)$311,663 
Basic weighted average common shares outstanding102,215 103,153 110,704 
Unvested and vested restricted stock units1,363 — 757 
Effect of assumed conversion of Convertible Senior Notes to common shares— — 7,230 
Diluted weighted average common shares outstanding (1)
103,578 103,153 118,691 
Diluted Earnings/(Loss) per Share
$0.46 $(2.57)$2.63 
(1)At December 31, 2023, the Company had approximately 3.8 million equity instruments outstanding that were included in the calculation of diluted EPS for the year ended December 31, 2023.  These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $11.89. These equity instruments may continue to have a dilutive impact on future EPS.